Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
183
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 11 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP METHOTREXATE (DIN 02562979) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02562979 | approved | health-canada-dpd |
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE TABLETS, USP (DIN 02562839) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02562839 | approved | health-canada-dpd |
| — | Eribulin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERIBULIN MESYLATE INJECTION (DIN 02560399) under ATC L01XX41 ERIBULIN. Indications are not published in the Drug… | DIN02560399 | approved | health-canada-dpd |
| — | Lifileucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as AMTAGVI (DIN 02560232) under ATC L01XL11 LIFILEUCEL. Indications are not published in the Drug Product Database — see… | DIN02560232 | approved | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02560208) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02560208 | approved | health-canada-dpd |
| — | Bosutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-BOSUTINIB (DIN 02560011) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product… | DIN02560011 | approved | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION (DIN 02559994) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in… | DIN02559994 | approved | health-canada-dpd |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02558815) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02558815 | approved | health-canada-dpd |
| — | Mitomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOMYCIN FOR INJECTION (DIN 02557762) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product… | DIN02557762 | approved | health-canada-dpd |
| — | Repotrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AUGTYRO (DIN 02557452) under ATC L01EX28 REPOTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02557452 | withdrawnsource: Cancelled Pre Marketsince Oct 17, 2025 | health-canada-dpd |
| — | Repotrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AUGTYRO (DIN 02557444) under ATC L01EX28 REPOTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02557444 | withdrawnsource: Cancelled Pre Marketsince Oct 17, 2025 | health-canada-dpd |
| — | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-NILOTINIB (DIN 02556626) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product… | DIN02556626 | approved | health-canada-dpd |
| — | Loncastuximab Tesirine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYNLONTA (DIN 02556138) under ATC L01FX22 LONCASTUXIMAB TESIRINE. Indications are not published in the Drug Product… | DIN02556138 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE INJECTION (DIN 02555468) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02555468 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2026 | health-canada-dpd |
| — | Talazoparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TALZENNA (DIN 02555077) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database —… | DIN02555077 | approved | health-canada-dpd |
| — | Talazoparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TALZENNA (DIN 02555069) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database —… | DIN02555069 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02554542) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02554542 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02554534) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02554534 | approved | health-canada-dpd |
| — | Hydroxyurea | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-HYDROXYUREA (DIN 02552582) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug… | DIN02552582 | approved | health-canada-dpd |
| — | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADHEROZA (DIN 02550970) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02550970 | approved | health-canada-dpd |
| — | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARMLUPEG (DIN 02550857) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02550857 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-SUNITINIB (DIN 02548062) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02548062 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-SUNITINIB (DIN 02548054) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02548054 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-SUNITINIB (DIN 02548046) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02548046 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-SUNITINIB (DIN 02548038) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02548038 | approved | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02547678) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02547678 | approved | health-canada-dpd |
| — | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-GEFITINIB (DIN 02547546) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product… | DIN02547546 | approved | health-canada-dpd |
| — | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-NINTEDANIB (DIN 02547538) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02547538 | approved | health-canada-dpd |
| — | Nintedanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-NINTEDANIB (DIN 02547511) under ATC L01EX09 NINTEDANIB. Indications are not published in the Drug Product… | DIN02547511 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02547287) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02547287 | approved | health-canada-dpd |
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as EUGIA-METHOTREXATE (DIN 02546515) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02546515 | approved | health-canada-dpd |
| — | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE FOR INJECTION (DIN 02544857) under ATC L01DB01 DOXORUBICIN. Indications… | DIN02544857 | approved | health-canada-dpd |
| — | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARSENIC TRIOXIDE FOR INJECTION (DIN 02541971) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published in… | DIN02541971 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02541777) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02541777 | approved | health-canada-dpd |
| — | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARSENIC TRIOXIDE FOR INJECTION (DIN 02540517) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published in… | DIN02540517 | approved | health-canada-dpd |
| — | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02537389) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product… | DIN02537389 | approved | health-canada-dpd |
| — | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as BUSULFAN FOR INJECTION (DIN 02536935) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product… | DIN02536935 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02536773) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02536773 | approved | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02536757) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02536757 | approved | health-canada-dpd |
| — | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTION (DIN 02536668) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02536668 | approved | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL INJECTION (DIN 02536056) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product… | DIN02536056 | approved | health-canada-dpd |
| — | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02535289) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product… | DIN02535289 | approved | health-canada-dpd |
| — | Ciltacabtagene Autoleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARVYKTI (DIN 02535270) under ATC L01XL05 CILTACABTAGENE AUTOLEUCEL. Indications are not published in the Drug… | DIN02535270 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02534096) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02534096 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02534088) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02534088 | approved | health-canada-dpd |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02534037) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02534037 | approved | health-canada-dpd |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02534029) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02534029 | approved | health-canada-dpd |
| — | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-GEFITINIB (DIN 02533685) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database… | DIN02533685 | approved | health-canada-dpd |
| — | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTION (DIN 02533111) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02533111 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ SUNITINIB (DIN 02532875) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product… | DIN02532875 | approved | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.